Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma Meeting Abstract
| Authors: | Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Weber, P. E. Y.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Mahave, M.; van Cutsem, E.; Tabernero, J.; Xu, L.; Sharan, K. P.; Bhagia, P.; Janjigian, Y. Y. |
| Abstract Title: | Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma |
| Meeting Title: | ESMO Asia Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2024 Dec 6-8 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-12-01 |
| Start Page: | S1453 |
| End Page: | S1454 |
| Language: | English |
| ACCESSION: | WOS:001401985200124 |
| DOI: | 10.1016/j.annonc.2024.10.154 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 128MO -- Source: Wos |
